Docket: 061002

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicants: Application No.: John D. Dobak, III

Date Filed:

10/008,999 12/07/2001

Title:

MEDICAL PROCEDURE

Group Art Unit:

3738

Examiner.:

David J. Isabella

Atty. Docket:

061002

RECEIVED

MAR 2 2 2004

TECHNOLOGY CENTER R3700

## INFORMATION DISCLOSURE STATEMENT (IDS)

Mail Stop DD Commissioner For Patents P.O. Box 1450 Arlington, VA 22313-1450

SIR:

In accordance with 37 C.F.R. §1.56 and in compliance with 37 C.F.R. §§1.97 and 1.98, the references listed on attached Form PTO/SB/08 and/or subsequently identified herein, are being submitted herewith for consideration by the United States Patent and Trademark Office.

I.	COPIES a.  b.  b.  copies	A legible copy of (i) each which caused it to be listed to be listed, is included her Any patents, publications not enclosed herewith we following applications where we have the second	U.S. and foreign patents; (ii) each d; and (iii) all other information or rewith.  or other information which are listed the previously cited by or submitted the previously cited the previously cited by or submitted the previously cited by the previously c	that portion which caused it ed on PTO/SB/08 which are d to the PTO in one of the
		U.S.C. §120:  U.S. Serial Number		U.S. Filing Date
II.	<u>CONCI</u> a. ⊠ b. □ c. □	Except as may be indicate other information are in th A concise explanation of listed that is not in the Eng	HE RELEVANCE (check at least or d below in (b) of this section, all of e English language (concise explan- the relevance of all patents, public glish language is as follows: information is provided for the Exan	f the patents, publications or ation not required). cations or other information
III. 🗀	The Ex	y be related to the prese	FED APPLICATION(S) following co-pending application( nt application. By bringing this does(do) not waive the confidentia	(these) applications to the
	Serial N	lo.	Filing Date	Art Unit

**FEES** 

, Docket: 061002

IV. 🗌	THIS ID a.□	OS IS BEING FILED UNDER 37 C.F.R. §1.97(b): (check one box) within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d) (37 C.F.R. §1.97(b)(1)). No fee or statement is required.
	b c	within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. §1.97(b)(2)). No fee or statement is required. before the mailing date of a first Office Action on the merits (37 C.F.R. §1.97(b)(3)). No fee or statement is required.
	d.	before the mailing date of a first Office Action after the filing of a request for continued examination under § 1.114 (37 C.F.R. § 1.97(b)(4)). No fee or statement is required.
v. 🗌	before the Allowan	DS IS BEING FILED UNDER 37 C.F.R. §1.97(c): (check one box) the mailing date of any of a Final Office Action under 37 C.F.R. §1.113, a Notice of ince under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the ion (See 37 C.F.R. §1.97(c)).  No statement; therefore, charge deposit account 50-1047 the fee set forth in 37 C.F.R. §1.17(p).  See the statement below. No fee is required.
VI. 🛛		OS IS BEING FILED UNDER 37 C.F.R. §1.97(d): fore payment of the issue fee and is accompanied by the following: a statement under 37 C.F.R. §1.97(e) as provided below; and charge deposit account 50-1047 the petition fee set forth in §1.17(p).
VII. 🛚		MENT UNDER 37 C.F.R. §1.97(e) (check only one box, if applicable) ersigned hereby states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of IDS; or
	b. 🔀	no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and to knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months
	c.	prior to the filing of this statement, or some of the items of information contained in the IDS were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application or, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the IDS was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement.
VIII.	<u>PAYME</u> □ ⊠	A check in the amount of is enclosed for the above-identified fee(s).  Please charge Deposit Account No. 50-1047 in the amount of \$180.00 for the above-indicated fee(s).
		indicated fee(s).  If Applicant has overlooked any additional fees, or if any overpayment has been made, the Commissioner is hereby authorized to credit or debit Deposit Account 50-1047.  Two Copies of this paper are attached for Deposit Account charges and debits.

It is Applicant(s)' opinion that the claims presently on file patently distinguish the present invention from each of these references. The above references are being cited only in the interests of

" Docket: 061002

candor and without any admission that they constitute statutory prior art or contain matter which anticipates the invention or which would render the same obvious, either singly or in a combination, to a person of ordinary skill in the art.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 50-1047.

Respectfully submitted,

Karin L. Williams
Attorney for Applicant(s)

Tel. 908-518-7700 Fax 908-518-7795

Reg. No. 36,721

MAYER FORTKORT & WILLIAMS
Customer Number 27774

**Enclosures:** 

₫ ₫ PTO/SB/08 References

Foreign Search Report

Other:

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited with sufficient postage

with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 on

and is addressed to Mail Stop DD, Commissioner for Patents,

P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Correspondence

<u>Debra Rosenbaum</u> Typed or Printed Name of Person Mailing Certificate

Docket: 061002 Please type a plus sign (+) inside this

PTO/SB/O8A (10-96)

Approved for use through 10/31/99, OMB 0651-0031 Patent and Trademark Office: U.S./DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to a collection of information unless it contains a valid OMB control number.

Cubatituta for	ute for form 1449A/PTO		Complete if Known		
Supstitute 101	101111 1443/07	10		Application Number	10/008,999
INFOF	RMATION	DISCLO	SURE	Filing Date	12/07/2001
				Application Number 10/008,999  Filing Date 12/07/2001  First Named Inventor John D. Dobak All  Group Art Unit 3738	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	.07	Group Art Unit	3738 EC. 77		
(use	as many she	eets as nece	ssary)	Examiner Name	David J. Isabella
Sheet	1	of	1	Attorney Docket Number	061002 Gr 004

	Г		100
Examiner	Cite	OTHER PRIOR ART—NON-PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial,	T <sup>2</sup>
Initials'	No.1	symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  HEDERER, G., et al.; "Animal Experiment Observations Regarding Cardiac Surgery under Intravascular Hypothermia"; Labgebbecjs Arch. U. Dtsch. A. Chir., Bd. 283, S. 601-625 (1957) (German article with English translation)	
•	A2	BEHMANN, F.W; "Heat Generation Control during Artificial Hypothermia: II. Theoretical Examinations"; Pflügers Archiv, Bd. 266, S. 422-446 (1958) (German article with English translation)	
	A3	BEHMANN, F.W., et al.; « Heat Generation Control during Artificial Hypothermia: I: Experimental Examination of the Influence of Anesthetic Depth"; Pflügers Archiv, Bd. 266, S. 408-421 (1958) (German article with English translation)	
	A4	BEHMANN, F.W., et al.; Intravascular Cooling, a Method to Achieve Controllable Hypothermia; Pflügers Archive, Vol. 263, pages 145-165 (1956) (German article with English translation)	
	A5	JACKSON, DONALD, et al; "Hypothermia: IV. Study of Hypothermia Induction Time with Various Pharmacological Agents (24617)"; Proc Soc Exp Biol Med.; 100(2): 332-335 (February 1959)	
	A6	BEHMANN, F.W.; "Heat Generation Control during Artificial Hypothermia, an article about the economic problem of trembling stages"; Pflügers Archive, Vol. 263, pages 166-187 (1956) (German article with English translation)	
	A7	BEHMANN, F.W.; "Regulation of heat production in experimental hypothermia of homothermal animals"; Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 228 (1-2): 126-128 (1956) (German article with English translation)	

Examiner	Date	
Signature	Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

12Unique citation designation number. 2Applicant is to place a check mark here if English language Translation is attached.